title: Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
abstract: In a multicenter phase II study, 30 patients with unresectable, locally advanced or metastatic squamous cell or adenocarcinoma of the esophagus were treated with folinic acid 200 mg/m2/d, 5-FU 300 mg/m2/d, and cisplatin 20 mg/m2/d intravenously for 5 days every 4 weeks. Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years. Six other patients (3 SCC, 2 of 16 with adenocarcinoma, 1 mixed histology) had a partial response with a median duration of 9 months (range 5 to 57 + months) for an overall response rate of 27%. A further 6 patients (20%) had stable disease. Grade 4 neutropenia occurred in 6 patients (20%), with 5 requiring antibiotics for associated fever. Other grade 4 toxicities were nausea and vomiting (1), anemia (1), and thrombocytopenia (1); there were three early deaths (emphysema, cardiac arrest, pulmonary embolism). This combination appears to be an active, convenient regimen for advanced esophageal cancer, resulting in prolonged remission and survival in some patients.
authors.affiliation: Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Ontario, Canada. ellen-warner@cancercare.on.ca
authors.forename: E
authors.initials: E
authors.lastname: Warner
authors.forename: J L
authors.initials: JL
authors.lastname: Jensen
authors.forename: C
authors.initials: C
authors.lastname: Cripps
authors.forename: K E
authors.initials: KE
authors.lastname: Khoo
authors.forename: R
authors.initials: R
authors.lastname: Goel
authors.forename: I A
authors.initials: IA
authors.lastname: Kerr
authors.forename: G A
authors.initials: GA
authors.lastname: Bjarnason
authors.forename: A L
authors.initials: AL
authors.lastname: Fields
authors.forename: A
authors.initials: A
authors.lastname: Hrincu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009864:Ontario; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil